Member access

4-Traders Homepage  >  Shares  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA

 (UNC)
0
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Latest news on UCB SA
6d ago UCB: Update on share capital, securities carrying voting rights and voting righ..
06/13 UCB: announces new results from phase 2b open-label extension study evaluating ..
06/12 UCB: Transparency notification of Vanguard Health Care Fund
06/11 UCB: to collaborate with CRELUX and 4SC Discovery to meet unmet needs in neurol..
05/29 UCB: to secure long-term partnership with UNITHER Pharmaceuticals for its Roche..
05/24 UCB: Transparency notification of The Capital Group Companies Inc.
05/16 UCB: and IBM Collaborate to Personalize Care for Epilepsy Patients
05/09 UCB: Acquisition of own shares (09 05)
05/02 UCB: ex-dividend day for annual dividend
04/25 UCB: UCB's shareholder meeting today
04/25 UCB: Slow Start but Outlook 2013 and Growth Prospects Confirmed
04/22UCB SA: quaterly earnings release
03/28 UCB: Acquisition of own shares
03/26 UCB: SA/NV - Convocation to the Annual General Shareholders' meeting
03/19 UCB: New data Released on Switching Parkinson's Disease Patients with Pre-Exist..
03/19 UCB: and Five Prime Therapeutics announce strategic discovery collaboration
03/14 UCB: Acquisition of own shares
03/11 UCB: successfully completes its fixed rate Bond issue
03/11 UCB: Acquisition of own shares
03/07 UCB: launches 7-year 3.75% fixed rate Retail Bonds
03/05 UCB: VIMPAT® (lacosamide) generates positive results in US Phase 3 monotherapy ..
02/27 UCB: in 2012: New Core Medicines Drive Growth
02/26 UCB: to license worldwide rights to tozadenant in Parkinson’s disease from Biot..
02/22 UCB: SA/NV - Convocation to the Extraordinary General Meeting
02/21 UCB: and ConfometRx announce new R&D partnership
02/20 UCB: announces regulatory filings for Cimzia® (certolizumab pegol) to treat pso..
02/11 UCB: Acceleration of Fracture Healing with CDP7851/AMG785 will not move into ph..
02/05 UCB: Accelerating focus on the patient
02/04 UCB: New single loading dose option for VIMPAT® (lacosamide) in the European Un..
2012 UCB: Astellas and UCB announce approval of Cimzia® (certolizumab pegol) in Japa..
2012 UCB: Neupro® (rotigotine transdermal patch) approved in Japan for Parkinson’s d..
2012 UCB: Announces New Data to Increase Understanding of Short- and Long-Term Clini..
2012 UCB: Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of ..
2012 UCB: to enter into an asset purchasing agreement with Exemed Pharmaceuticals fo..
2012 UCB: and NewBridge Pharmaceuticals Partner for Middle East and African markets
2012 UCB: commences phase 3 lacosamide study in Asia
2012 UCB: RAPID™-PsA study showed that certolizumab pegol improved signs and symptom..
2012 UCB: announces data on Cimzia® (certolizumab pegol) for patients with moderate ..
2012 UCB: RAPID™-axSpA study showed certolizumab pegol reduced signs and symptoms of..
2012 UCB: Have you made a difference for people with epilepsy through journalism? Fi..
2012 UCB: Interim Report for the first nine months of 2012
2012 UCB: announces retirement of Executive Vice President and General Counsel and a..
2012 UCB: scientist awarded visiting professorship at Oxford Medical School
2012 UCB: Announces Third Research Collaboration With Harvard University
2012 UCB: announces top-line phase 2 results for olokizumab in rheumatoid arthritis
2012 UCB: Transparency notification of Capital Research and Management Company and T..
2012 UCB: Launches Neupro® in the U.S. to treat Parkinson’s Disease and Restless Leg..
2012 UCB: Launches Neupro® in the U.S. to Treat Parkinson's Disease and Restless Leg..
2012 UCB: Acquisition of own shares
2012 UCB: wins “Company Of the Year” at the European Mediscience Awards
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: expands in Brazil
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: ex-dividend day for annual dividend
2012 UCB: Interim Report – first three months 2012
2012 UCB: First Assessment of Individual RLS Domains in New Post-Hoc Analyses of Neu..
2012 New Amgen CEO must win investors with payouts, deals
2012 UCB: New Neupro® data in Parkinson’s disease and Restless Legs Syndrome to be p..
2012 UCB: Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at th..
2012 UCB: Journalists recognised for excellence in reporting on epilepsy
2012 UCB: Transparency notification of Vanguard Health Care Fund
2012 UCB: marks World Parkinson’s Disease Day with new ‘Parkinson’s Well-Being Map™’
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: Transparency notification of Pharmahold SA – Cosylva SA – Compar Finance S..
2012 UCB: Neupro® approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syn..
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: SA/NV: Convocation Annual Shareholders' Meeting
2012 UCB: Acquisition of own shares
2012 UCB: New members on UCB's Board of Directors
2012 UCB: Transparency notification of Pharmahold SA
2012 UCB: Industry and academia join forces as UCB and Oxford University announce ne..
2012 UCB: Acquisition of own shares in the framework of employees’ long-term incenti..
2012 UCB: CEO to chair Innovative Medicines Initiative board
1  2  3  4Next
Advertisement
Chart
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Income Statement Evolution
UCB SA : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Stay Connected :
Copyright © 2013 Surperformance. All rights reserved.